Deutsche Biotech Innovativ AG

Equities

DBI

DE000A0Z25L1

Biotechnology & Medical Research

End-of-day quote BOERSE DUESSELDORF Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.35 ^EUR	-10.60%		+35.00%	-82.80%

2023	Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2018	Adrenomed AG announced that it has received €24.2 million in funding from Deutsche Biotech Innovativ AG, Wellington Ventures, HBM Healthcare Investments Ltd., and other investors	CI

Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022

June 05, 2023 at 03:11 pm EDT

Deutsche Biotech Innovativ AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was EUR 0.23644 million compared to EUR 0.223 million a year ago.

Latest news about Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-05	CI
Adrenomed AG announced that it has received €24.2 million in funding from Deutsche Biotech Innovativ AG, Wellington Ventures, HBM Healthcare Investments Ltd., and other investors	18-11-22	CI
Deutsche Biotech Innovativ AG Completes Preclinical Studies with Adrecizumab, an Innovative Drug Candidate for Treating Sepsis	15-08-06	CI
Deutsche Biotech Innovativ AG Successful Further Development of Sepsis and Cancer Drugs	15-06-12	CI

Chart Deutsche Biotech Innovativ AG

Duration

Period

More charts

Company Profile

Deutsche Biotech Innovativ AG, formerly Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The Company's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DEUTSCHE BIOTECH INNOVATIV AG	-82.80%	1.37M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research